Cidara Therapeutics (CDTX) Peer Comparison

$221.38

$0.00 (0.00%)

As on 08-Jan-2026 09:30EDT

Market cap

$6,962 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

16.5

Div. Yield

0 %

Edit

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Market cap ($ Mln)	6,962	145
Revenue ($ Mln)	--	33
Net Profit ($ Mln)	-184.74	-70.08
Net Margin (%)	--	-211.21
RoE (%)	-65.50	--
Price to Earnings	--	--
Price-To-Book	16.48	32.03

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Operating Revenue	0.00	33.18
Cost of Revenue	128.34	0.69
Gross Profit	1.28	40.50
Operating Expenses	150.46	100.27
Operating Profit (EBIT)	-195.46	-67.38
Other Income	0.00	0.00
Profit before Tax	-184.80	-70.08
Provision for Tax	0.00	-1.22
Profit after Tax (Net Income)	-184.74	-70.08
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Shareholder's Funds	422.39	-59.54
Minority Interest	0.00	0.00
Non-Current Liabilities	0.42	78.95
Current Liabilities	95.84	43.27
Total Liabilities	214.80	144.66

Assets ($ Mln)

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Non-Current Assets	75.83	2.70
Current Assets	442.82	59.99
Total Assets	214.80	144.66
Total Debt*	1.98	2.29
Net Current Assets	346.98	16.72

Cashflow ($ Mln)

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Cash From Operating Activities	-176.53	-82.34
Cash Flow from Investing Activities	-0.13	11.44
Cash from Financing Activities	337.06	4.09
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
ROCE (%)	-207.67	-154.06
ROE (%)	-65.50	-505.14
ROA (%)	-44.99	-40.77
EBIT Margin (%)	--	-202.94
Net Margin (%)	-13,319.76	-211.21
Cash Profit Margin (%)	--	0.00

Growth Ratios

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Revenue Growth (%)	-0.95	-4.76
EBIT Growth (%)	-340.88	4.06
Net Profit Growth (%)	-50.03	6.08
EPS Growth (%)	45.89	8.07
Book Value Growth (%)	53.43	-5,686.95

Valuation Ratios

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Price / Earnings	-1.54	-0.10
Price / Book Value	1.60	-0.74
Dividend Yield (%)	--	--
EV/EBITDA	-0.43	1.56
Market Cap ($ Cr)	--	--

Solvency Ratios

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.00	-0.04
Current Ratio	4.62	1.39
Quick Ratio	4.62	1.39
Interest Coverage	--	-24.52

Operating Efficiency Ratios

	Cidara Therapeutics (CDTX)	Mersana Therapeutics (MRSN)
Debtors to sales (%)	132.86	0.51
Asset Turnover	0.00	0.19
Receivable days	2,569.64	0.00
Inventory Days	26.24	--
Payable days	15.88	1,306.76
Cash Conversion Cycle	2,580.00	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly